Stockwinners Market Radar for July 21, 2022 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

20:04 EDT PennyMac Financial director sells $2M in common stock - In a regulatory filing, PennyMac Financial disclosed that its director Joseph Mazzella sold 40K shares of common stock on July 19th in a total transaction size of $2.0M.

18:55 EDT Northrop Grumman, NASA successfully test SLS rocket motor - The company states: "Northrop Grumman and NASA successfully conducted a full-scale static fire of NASA's Space Launch System, or SLS, rocket motor, known as Flight Support Booster-2. The five-segment solid rocket booster is the world's largest solid rocket motor and will provide more than 75 percent of the SLS rocket's initial thrust during launch. Over 300 measurement channels assessed the 154-foot-long solid rocket booster as it fired for just over two minutes producing upwards of 3.6 million pounds of thrust. Today's test evaluates new materials and demonstrates a new motor ignition system and an electronic thrust vector control system that steers the motors to provide data for the development of the next-generation Booster Obsolescence and Life Extension boosters. Northrop Grumman was awarded a contract to develop the BOLE booster in December 2021. The award also included follow-on production and flight sets for Artemis IV through Artemis VIII, and a BOLE booster set for Artemis IX."

18:26 EDT Dow Inc. CEO: Demand is still robust - In an interview on CNBC's Mad Money, Jim Fitterling said the consumer is strong and demand in many areas is robust. He is bullish on oil, and noted demand for oil derivatives has been strong. The company is progressing with its decarbonizing strategy and has more than $1B of CapEx per year devoted to it. Dow's balance sheet is clean and "as strong as ever," he added.

17:29 EDT Liminal BioSciences discontinues development of fezagepras - Liminal BioSciences announced that it has discontinued development of fezagepras. The decision to discontinue the development of fezagepras is based on results from the Phase 1a single ascending dose, or SAD, clinical trial, which indicated that fezagepras was significantly inferior compared to Sodium Phenylbutyrate as a nitrogen scavenger. The Phase 1a SAD clinical trial of fezagepras initiated in May 2022 was designed as a head-to-head comparison with Sodium Phenylbutyrate to provide us with further data to determine whether fezagepras was worth developing for one of the potential indications where nitrogen scavenging is beneficial. The recommendation to stop the development program for fezagepras was not based on safety concerns.

17:28 EDT Novanta to replace Six Flags in the S&P 400 at open on 7/26 - Novanta (NOVT) will replace Six Flags Entertainment (SIX) in the S&P MidCap 400, and Six Flags will replace Natus Medical (NTUS) in the S&P SmallCap 600 effective prior to the opening of trading on Tuesday, July 26. ArchiMed acquired Natus Medical in a deal that closed today. Six Flags Entertainment is more representative of the small-cap market space.

17:15 EDT CEO of Verve Therapeutics Sekar Kathiresan sells $1.5M in shares - The CEO of Verve Therapeutics Sekar Kathiresan disclosed in a filing that he sold 50,000 shares of company stock at $29.90 per share on July 19, for a total transaction amount of $1,495,000.

17:13 EDT Seagate says macro events weighing on near term performance - Says lockdowns in Asia to impact near term revenue growth. Expects customers to reduce inventory levels. Says maintaining "prudent cost controls" across the business. Says secular demand trends for data storage products remain intact. Says U.S. cloud data center demand remains strong. Comments taken from Q4 earnings conference call.

17:05 EDT Intuitive Surgical raises FY22 procedure growth view to 14%-16.5% from 12%-16% - Says procedure growth so far in first half has been healthy. Sees FY22 gross profit margin 69%-70% of net revenue. Sees FY22 operating expense growth 23%-25%. Sees FY22 tax rate 22%-24%. Says semiconductor and raw material suppliers giving the company choppy delivery times. Says supply constraints negatively impacted placements by 5% in Q2. Says financial pressures have increased on hospitals. Says a lot are tightening operational budgets. Says expects volume of trade-ins to be significantly lower in 2022. Says procedures in China remained below expectations. Comments and guidance taken from Q2 earnings conference call.

16:53 EDT Mattel backs FY23 operating margin view of 16%-17%

16:46 EDT Vera Bradley announces CEO transition - Vera Bradley "announced the planned retirement of President and Chief Executive Officer Robert Wallstrom. Wallstrom will remain President and CEO until a successor is named, which is expected by the beginning of 2023. Wallstrom will work with the Board of Directors in their national search for his successor."

16:43 EDT Tenet Healthcare jumps over 8% to $64.50 after Q2 earnings beat

16:39 EDT Seagate drops 11% to $74.30 after Q4 results, Q1 guidance miss estimates

16:37 EDT Seagate drops 11% to $74.05 after results miss estimates - Peer Western Digital (WDC) is trading down 6% to $47.29 in after-hours trading.

16:33 EDT Santander Mexico announces structural changes to CEO position - Banco Santander Mexico, S.A., Institucion de Banca Multiple, Grupo Financiero Santander Mexico announced that its Board of Directors approved the appointment of Felipe Garcia Ascencio as CEO of the Bank, replacing Hector Grisi Checa. Hector Grisi will remain as Executive Chairman and Chief Executive Officer of Grupo Financiero Santander Mexico until December 31, 2022. The Board also approved the creation of two Vice-presidencies. The Vice-presidency of Administration and Finance, to be led by Didier Mena Campos, who currently holds the position of CFO, and the Vice-presidency of Consumer, Commercial and Institution Business Banking, to be held by Pablo Fernando Quesada Gomez, who heads the Consumer, Commercial and Institution Business Banking department.

16:32 EDT CenterPoint Energy raises quarterly dividend to 18c from 17c per share - Payable on September 8 to shareholders of record at the close of business on August 18.

16:26 EDT Boston Beer drops 10% to $303.40 after lowering FY22 EPS guidance

16:25 EDT Capital One drops 5% to $108.50 after Q2 results miss estimates

16:23 EDT FOX Nation expands distribution to FuboTV - FOX News Media (FOX) has expanded distribution of its direct-to-consumer subscription streaming service FOX Nation across live TV streaming platform FuboTV (FUBO), announced FOX Nation President Jason Klarman. In making the announcement, Klarman said, "We're delighted to partner with FuboTV to offer FOX Nation as part of their growing content offering and bring our loyal audience more ways to access the wide variety of signature content that they crave." FuboTV subscribers now have the option to add FOX Nation to their subscription for $5.99 a month.

16:20 EDT Verisk names Elizabeth Mann CFO - Verisk (VRSK) announced that Elizabeth Mann has been named executive vice president and chief financial officer for Verisk, effective September 15. An accomplished financial leader, Mann comes to Verisk from S&P Global (SPGI), where she was chief financial officer for the Ratings and Mobility divisions, and prior to that senior vice president of capital management. She also held roles of increasing responsibility at Goldman Sachs, including managing director of the firmwide strategy group and the technology, media & telecom investment banking group. Before joining corporate America, Mann earned a doctorate in Mathematics from the University of Oxford, and she was Moore Instructor & National Science Foundation Postdoctoral Fellow at the Massachusetts Institute of Technology.

16:16 EDT Snap shares plunge 24% after reporting Q2 results

16:15 EDT Snap sees Q3 DAU 360M, says revenue approx. flat on y/y basis so far - Thus far in Q3, revenue is approximately flat on a year-over-year basis, Snap said. "Forward-looking visibility remains incredibly challenging, and it is unclear how the headwinds we observed in Q2 will evolve as we move through Q3. Given this, we do not intend to provide financial guidance for Q3. That said, it is clear that our rate of revenue growth has slowed considerably and we must adapt our investment strategy. We intend to substantially slow our rate of hiring, as well as the rate of operating expense growth."

16:14 EDT Snap has substantially reduced rate of hiring

16:13 EDT Hanger enters agreement to be acquired by Patient Square Capital for $1.25B - Hanger "announced that it has entered into a definitive agreement to be acquired by Patient Square Capital, a dedicated health care investment firm. Under the terms of the agreement, which has been unanimously approved by Hanger's Board of Directors, Hanger stockholders will receive $18.75 in cash per share, representing an approximately 29% premium to the 30 calendar day volume-weighted average price ending July 20, 2022, and a total enterprise value of approximately $1.25 billion. Upon completion of the transaction, Hanger will become a privately held company, and its common stock will no longer be traded on the New York Stock Exchange".

16:12 EDT Snap not providing guidance for revenue, adjusted EBITDA for Q3 - "Given uncertainties related to the operating environment, we are not providing our expectations for revenue or adjusted EBITDA for the third quarter of 2022," Snap said.

16:12 EDT Snap board authorizes $500M Class A stock repurchase program - Snap Inc. also announced its Board of Directors has authorized a stock repurchase program of up to $500M of its Class A common stock.

16:11 EDT Snap CEO: Results for Q2 'do not reflect our ambition' - "While the continued growth of our community increases the long-term opportunity for our business, our financial results for Q2 do not reflect our ambition," said Evan Spiegel, CEO. "We are evolving our business and strategy to reaccelerate revenue growth, including innovating on our products, investing heavily in our direct response advertising business, and cultivating new sources of revenue to help diversify our topline growth."

16:10 EDT 3D Systems partners with Fleet Space Technologies on RF patch antennas - 3D Systems announced a new collaboration with Fleet Space Technologies which has led to the production of RF patch antennas for use on their Alpha satellite constellation. The combination of Fleet Space Technologies' design along with the expertise of 3D Systems' Application Innovation Group allowed them to architect a complete additive manufacturing solution - which includes process development and bridge production on its DMP Flex 350 - enabling the companies to move from Fleet Space's existing RF patch design to small batch production in just three weeks. Fleet Space Technologies is bringing a DMP Flex 350 printer into service at their headquarters in Beverley, Adelaide allowing the company to bring production of its patch antennas in-house. The printer will be used to create RF patch antennas for each of the Alpha satellites operating in a constellation in low earth orbit as part of Fleet Space Technologies' ExoSphere initiative for mining exploration with minimal environmental impact. Fleet Space Technologies' engineering team designed the antenna to meet size, weight, and performance requirements while minimizing the need for post-processing. Not only is argon gas consumption heavily reduced, but the vacuum chamber architecture also produces a surface finish with fine feature detail which minimizes signal losses.

16:08 EDT Tandem Diabetes acquires Capillary Biomedical, terms not disclosed - Tandem Diabetes "announced its acquisition of infusion set developer, Capillary Biomedical. Financial terms were not disclosed."

16:01 EDT Seagate trading halted, news pending

15:13 EDT Freeman Capital discloses 6.21% stake in Bed Bath & Beyond - Jake Freeman of Freeman Capital's FCM BBBY Holdings disclosed ownership of 4,968,000 shares of Bed Bath & Beyond's common stock, which amounts to a 6.21% stake.

14:11 EDT Bethesda's 'Elder Scrolls Online' hits 21M players - Bethesda's massively multiplayer online role-playing game "The Elder Scrolls Online" has achieved 21M players since its 2014 release. Bethesda is a wholly-owned subsidiary of Microsoft. Reference Link

14:04 EDT Coinbase files petition asking SEC to make applicable rules for crypto firms - Cryptocurrency infrastructure and tech firm, Coinbase, said, in part in an earlier blog post: "Today, there is a robust crypto market in the U.S. That market includes thousands of different digital assets, crypto companies, and decentralized financial products, and is regulated at every level of government, including by multiple federal agencies in the United States. Yet despite the growth that has happened in recent years, close examination reveals a glaring deficiency in this market...Crypto assets that are securities need an updated rulebook to help guide safe and efficient practices...Securities law is thus not well-suited to govern digital assets...If the SEC were to write rules permitting the tokenization of securities, the opportunities for innovation would be significant. The crypto markets could be expanded to offer crypto securities, subject to SEC regulation and governance, thereby giving investors new ways to invest in crypto. And opening debt and equity securities to tokenization would promote efficiency and resiliency in traditional markets.While the SEC has refused to develop new rules for digital asset securities, several governments and other organizations around the world are well on their way to new, workable crypto rules." Reference Link

13:00 EDT Interim data from Acclaim-1, Acclaim 2 trials expected soon, Genprex CEO says

13:00 EDT Genprex ONCOPREX first of its kind to be used for cancer in humans, CEO says

12:32 EDT Activision Blizzard workers stage walkout to 'end gender inequity' - According to ABK Workers Alliance, Activision Blizzard's (ATVI) internal employee rights advocacy group, employees at the game company are walking out to "end gender inequity" on July 21st, the one year anniversary of the DFEH vs. Activision Blizzard Lawsuit. This walkout will be held both in person, and virtually by employees across ABK. The alliance is demanding that all ABK employees have the option to choose fully remote work; that all staff currently residing in locations passing discriminatory legislation must be offered relocation assistance to a safe state or country; that the company must provide Cost of Living adjustments to the compensation of employees who relocate to a safe state or country to avoid discriminatory legislation; that the game maker must ensure its health insurance partner continues to cover transgender and reproductive healthcare, including abortion; that management must immediately and transparently enact plans to allow relocation from locations which are passing anti-abortion, anti lgbtq+, or any other demonstrably discriminatory legislation; that staff must be included in the audit/report requested by shareholders to make sure that any sexual harassment audit was conducted fairly and exhaustively; that leadership must agree to hold regular meetings with members of the worker led Committee Against Sex and Gender Discrimination; and that the company must sign a labor-neutrality agreement like Microsoft (MSFT) did. The Fly notes that Activision Blizzard earlier this year agreed to be acquired by Microsoft. Reference Link

12:28 EDT Altice USA trading resumes

12:21 EDT Altice USA jumps 6% to $9.71 after Bloomberg says exploring Suddenlink sale

12:01 EDT Zurn Elkay increases quarterly dividend to 7c per share - Zurn Elkay Water Solutions announced that its Board of Directors declared a quarterly common stock dividend of 7c per share payable in cash on September 7, 2022 to stockholders of record as of August 19, 2022.

12:00 EDT W&T Offshore falls -10.9% - W&T Offshore is down -10.9%, or -48c to $3.97.

12:00 EDT Insteel falls -15.4% - Insteel is down -15.4%, or -$6.28 to $34.53.

12:00 EDT Cano Health rises 13.3% - Cano Health is up 13.3%, or 76c to $6.47.

11:58 EDT CC Neuberger Principal Holdings II shareholders approve Getty Images deal - CC Neuberger Principal Holdings II (PRPB), a publicly traded special purpose acquisition company formed through a partnership between CC Capital and Neuberger Berman, announced earlier that at its extraordinary general meeting of shareholders held on July 19, CC Neuberger shareholders voted to approve and adopt the previously announced business combination with Getty Images. The business combination is expected to close on July 22, subject to the satisfaction or waiver of customary closing conditions. Upon closing of the business combination, the combined company will change its name to Getty Images Holdings, Inc., and common stock and warrants of the combined company are expected to begin trading on the New York Stock Exchange on July 25 under the symbol "GETY" and "GETY WS," respectively. Craig Peters, CEO of Getty Images, said: "We are pleased the shareholders approved our merger with CC Neuberger, and we look forward to returning to public markets. As a public company we will continue moving the world with content that we believe can't be found anywhere else, advanced technology, exclusive partnerships with some of the best visual creators in the world, and an archive dating back to the beginning of photography and videography."

11:42 EDT Penske Automotive dividend increased by 3c to 53c per share - Penske Automotive Group announced that its board of directors has increased the company's dividend by 3c per share, or 6%, to 53c per share. The dividend is payable September 1 to shareholders of record on August 10. "Based on our continued strong cash flow and the strength of the company's diversified business model, we are delighted to provide our shareholders with a three cent increase in the cash dividend," said Penske Automotive Group President, Robert Kurnick, Jr.

11:12 EDT Akamai up 4% after blog report claims PE firm lining up possible bid - Shares of Akamai Technologies are up $3.69, or 4%, to $93.48 after Street Insider claimed in a post to its site that a source said a private equity firm is supposedly in talks with banks to secure financing to launch a potential formal bid for the company. "Given that funding markets are tighter due to rising interest rates and macro concerns, it is unclear how successful the financing will be and if it will lead to a bid," the report added.

10:54 EDT United Airlines sees Q4 capacity down 10% vs. 2019, 2022 capacity down 13% - Sees Q3 CASM-ex up 16%-17% vs. 2019, with Q4 CASM-ex up about 14%, FY22 CASM-ex up about 16%, and FY23 CASM-ex up about 5%.

10:51 EDT United Airlines seea Q3 capacity down about 11% vs. 2019 - Sees Q3 TRASM up 24%-26% vs. 2019.

10:45 EDT United Airlines dedicated to hiring at least 200 a month, company says

10:42 EDT United: Q3 results expected to continue to accelerate back to 2019 margin

10:39 EDT United Airlines assuming 'this is the new normal' for fuel prices

10:36 EDT United sees continuing improvement in revenue, EPS, margins going forward

10:36 EDT United Airlines 'optimistic' about near-, short-term, says CEO

10:35 EDT United Airlines continuing to see strong demand, says CEO

10:24 EDT Freeport-McMoRan says execution of long-term plans 'on track' - Says team is sufficient in managing challenge circumstances. Says prepared to respond to a weakening market if necessary. Says Lone Star mine continues to perform above design capacity. Says advancing leach recovery initiatives across Americas portfolio. Says significant value enhancing opportunity for the company. Says advancing plans for Bagdad 2X project. Says Cerro Verdo had recent positive results on explorations. Says increased stacking rates at El Abra. Says continuing to evaluate alternatives at El Abra. Says cost position at Grasberg is exceptional. Says advancing long-term development for Kucing Liar.

10:17 EDT Huntington Bancshares: Buybacks to be 'de minimis' for remainder of year

10:10 EDT Huntington Bancshares sees 2022 coming together 'quite well'

10:04 EDT Cano Health, Oak Street rally after Amazon buys One Medical - Shares of Cano Health (CANO), Oak Street Health (OSH) and CareMax (CMX) are rallying after Amazon.com (AMZN) announced it was acquiring 1Life Healthcare (ONEM) for $18 per share of $3.9B.

10:03 EDT Huntington Bancshares: 2022 'bringing its own set of unique challenges' - Comments taken from Q2 earnings conference call.

10:00 EDT Carnival plc falls -12.3% - Carnival plc is down -12.3%, or -$1.19 to $8.47.

10:00 EDT Insteel falls -13.6% - Insteel is down -13.6%, or -$5.57 to $35.24.

10:00 EDT Oak Street Health rises 12.3% - Oak Street Health is up 12.3%, or $3.11 to $28.37.

09:59 EDT Borr Drilling Limited trading halted, news pending

09:58 EDT PPG approves 5% dividend increase to 62c per share - The board of directors of PPG approved a 3-cents-per-share increase in the company's dividend, declaring a regular quarterly dividend of 62c per share. The increase is payable Sept. 10 to shareholders of record Aug. 10. PPG's prior quarterly dividend was 59c per share. "We are pleased to continue PPG's legacy of rewarding our shareholders with an increase in our per share dividend, reflecting the continued, strong confidence that PPG's Board and management team have in our ability to generate and grow our operating cash flow," said Michael McGarry, PPG chairman and CEO.

09:55 EDT Amazon says 100,000 Rivian vehicles expected across U.S. by 2030

09:54 EDT ITHAX Acquisition Corp trading resumes

09:51 EDT Healthcare Capital Corp trading resumes

09:47 EDT Ampco-Pittsburgh falls -9.7% - Ampco-Pittsburgh is down -9.7%, or -43c to $4.00.

09:47 EDT Carnival falls -12.3% - Carnival is down -12.3%, or -$1.36 to $9.73.

09:47 EDT Blue Apron rises 7.8% - Blue Apron is up 7.8%, or 25c to $3.44.

09:46 EDT Healthcare Capital Corp trading halted, volatility trading pause

09:44 EDT ITHAX Acquisition Corp trading halted, volatility trading pause

09:22 EDT ENG enters marketing, technology agreement with OiLSERV - ENG announced the signing of a marketing and technology agreement with OiLSERV FZCO, an integrated oilfield services company in the Middle East and North Africa region and headquartered in Dubai. Under the agreement, OiLSERV has paid ENG an undisclosed amount for the exclusive rights to market ENG's proprietary small-scale gas to liquids technology for a period of ten years in the countries of Iraq, Libya, Algeria, and the United Arab Emirates.

09:21 EDT Entravision becomes authorized sales partner of Meta Platforms - Entravision (EVC) announced that it has become the authorized sales partner of Meta Platforms (META) in Honduras and El Salvador. Through its business unit, Entravision Cisneros Interactive, Entravision will provide support, consulting, training and billing in local currency to help businesses achieve their advertising goals.

09:20 EDT NOAA contracts with Planet to gain 'situational awareness' of oil spills debris - Planet Labs PBC announced a new contract with the National Oceanic and Atmospheric Administration. The organization is leveraging Planet's PlanetScope and SkySat products to evaluate oil spills, track marine debris, detect vessels, and identify large marine mammals like whales. In 2004, Hurricane Ivan caused severe damage in the Gulf of Mexico, including the collapse and sinking of an oil platform. Crude oil from this platform continued to leak for over a decade, in what would become the longest running oil spill in United States history. NOAA began tracking the region with government-provided satellite data to generate reports on the situation. In 2018, NOAA reached out to Planet to explore how having a perspective of change on a near-daily basis around the platform could help inform their work. "With rapidly changing activity in the ocean - from increasingly severe storms to growing industrial demands - I'm so glad that NOAA is able to use our datasets to continue their vital efforts to protect coastal communities and ecosystems from hazards like oil spills and illegal fishing," said Planet Federal's Vice President Jon Powers.

09:19 EDT Vonage announces occurrence of fundamental change to senior notes - Vonage announced that each of its acquisition by Ericsson and the related delisting of its common stock from the Nasdaq Global Select Market, which have occurred effective July 21, 2022, constitute a "Fundamental Change" and a "Make-Whole Fundamental Change" as defined under the indenture dated June 14, 2019, as supplemented, governing Vonage's 1.75% Convertible Senior Notes due 2024. Vonage has designated the Fundamental Change Repurchase Date as August 19, 2022. At any time prior to the close of business on the business day immediately preceding the Fundamental Change Repurchase Date, holders of the Notes may elect to require Vonage to purchase all or any portion of such holder's Notes at a repurchase price equal to 100% of the principal amount of the Notes to be repurchased, plus accrued and unpaid interest to, but excluding, the Fundamental Change Repurchase Date. In addition, holders of the Notes have the right to elect to convert their Notes into an amount of cash equal to $1,343.81 for each $1,000 principal amount of Notes surrendered for conversion at any time during the period that begins on, and includes, the Effective Date and ends on, and includes, the business day immediately preceding the Fundamental Change Repurchase Date.

09:17 EDT SuperCom secures new electronic monitoring contract in South California - SuperCom announced that it has secured a new contract to deploy its Pure Security suite of electronic monitoring with a new customer in South California. This customer is a long-standing provider of products and services to the Criminal Justice market with primary operations in the southern part of California. SuperCom's proprietary electronic monitoring products and robust business model working directly with government agencies as well as electronic monitoring service providers were both instrumental in securing the contract. The contract is structured as a per unit per day lease model, with billing at the end of each month, for the use of the PureSecurity suite.

09:15 EDT Karyopharm, Menarini Group receive EC marketing approval for NEXPOVIO - Karyopharm Therapeutics and the Menarini Group, a privately-held, leading international pharmaceutical company, announced that the European Commission has granted Marketing Authorisation for NEXPOVIO, a first-in-class, oral exportin 1 inhibitor, in combination with once-weekly bortezomib and low-dose dexamethasone for the treatment of adults with multiple myeloma who have received at least one prior therapy. With this approval for the extension of NEXPOVIO's indication in the European Union, the conditional marketing authorisation is now converted to a full approval. The marketing authorisation, which marks the second indication for NEXPOVIO, is valid in all 27 member states of the EU as well as Iceland, Liechtenstein, Norway, and Northern Ireland. Stemline Therapeutics B.V., a wholly owned subsidiary of the Menarini Group, will be responsible for all commercialization activities in Europe.

09:14 EDT Sumo Logic delivers 3-step onboarding for Kubernetes observability - Sumo Logic unveiled a new process to deliver Kubernetes observability in just a few clicks. This simplified process streamlines the Sumo Logic collection process and ensures faster time-to-value for Kubernetes observability. This new experience makes it easy for developers to get up and running quickly with Kubernetes observability by: Establishing appropriate collection for the Kubernetes environment with the proper metadata. Installing the relevant app dashboards to view data and help diagnose and troubleshoot issues. Validating automatically generated alerts.

09:12 EDT Interpublic Group announces senior leadership changes - Interpublic Group announced senior leadership changes that will see a number of outstanding, tenured executives assume significant new responsibilities within the holding company. At McCann Worldgroup, Daryl Lee, previously the Global CEO of IPG Mediabrands, has been named Global CEO. Eileen Kiernan has been named Global CEO of IPG Mediabrands, succeeding Lee in that role. Bill Kolb, the current CEO of McCann Worldgroup, will remain Chairman of the division. While these changes take effect immediately, the three executives will continue working with their existing teams and clients over the next month to ensure that all necessary transitional actions related to their new roles are complete by September 6, 2022.

09:11 EDT Shell comments on dismissal of Dutch investigaton into OPL 245 - Shell plc made a statement after the Dutch Public Prosecutor's office announced it had dismissed its investigation into bribery allegations related to Oil Prospecting Licence, or OPL, 245 in Nigeria. "We welcome today's decision, which marks an end to the criminal investigation in The Netherlands. It follows the Milan Public Prosecutor's appeal withdrawal earlier this week, which ended all criminal proceedings and confirmed the Milan Tribunal's decision to acquit Shell and four of our former employees in March 2021. The Milan Public Prosecutor acknowledged that there was no evidence of a corrupt agreement or corrupt payments, that this case should end because it has no foundations, and that the defendants have the right to see the end of criminal proceedings, having endured seven years of suffering. Today's dismissal underscores what we have long maintained - that there was no case to answer for Shell or its former employees regarding the 2011 OPL 245 settlement, and that this case should have never been brought."

09:09 EDT Backblaze appoints Gavin as CMO - Backblaze announced that Kevin Gavin has joined the company as chief marketing officer, CMO, to lead the company's marketing efforts. "The addition of a seasoned CMO furthers the company's scaling of its growth initiatives following its recent IPO in November, 2021. Gavin brings extensive marketing and public company experience as CMO and expands Backblaze's in-house expertise to deepen the company's customer engagement and grow its brand awareness," the company said.

09:08 EDT Blink Charging enters agreement with Winslow, NJ to deploy five EV chargers - Blink Charging announced it has entered into an agreement with the Township of Winslow, N.J. to deploy five Blink IQ 200 dual port fast Level 2 EV chargers to be installed, providing 10 charging ports. The Township of Winslow will own and operate all the new EV chargers. The chargers have been deployed using Blink's local load management, which allows one IQ 200 dual port charger to be deployed on a single 100-amp circuit while providing up to 80 amp of output. "We are delighted to see how the Township of Winslow is being forward leaning when it comes to the future of transportation and addressing the infrastructure needs early," said Brendan Jones, President of Blink Charging. "With the new Blink IQ 200s, Township of Winslow residents can have confidence that their township's charging infrastructure is well positioned to meet their charging needs today and to serve the EVs of tomorrow."

09:06 EDT Sidus Space completes fabrication of first set of hardware in NASA program - Sidus Space announced that it has completed the fabrication of the first set of hardware in support of NASA's Artemis Program and their Space Launch System, or SLS, manned vehicle. As a subcontractor, Sidus is responsible for the build, qualification, and testing of Umbilical Quick Disconnects for the Environmental Control System, or ECS, on the Universal Stage Adapter for NASA's SLS. The fabrication of the first set of hardware was completed to support umbilical testing at Jacob's Launch Equipment Test Facility, or LETF, at Kennedy Space Center and was delivered last week. NASA reviewed and approved the hardware earlier this month.

09:06 EDT CareCloud to showcase digital health solutions at 2022 FIME - CareCloud announced it will exhibit at the 2022 Florida International Medical Expo. In addition, Patti Peets, CareCloud's Senior Vice President of Sales, will present how the Company's digital health offerings can help medical practices improve patient engagement through the latest technologies and services. The event will be held at the Miami Convention Center from July 27-29, 2022.

09:05 EDT Fresh Vine announces improvements to e-commerce site - Fresh Vine Wine announced a number of improvements to its e-commerce site, www.freshvinewine.com, that will offer the ultimate in convenient shopping experience, a reduction in shipping rates on all purchases, while also adding new perks for its Wine Club members.

09:04 EDT Skechers, Tokidoki partner on global footwear collaboration - Tokidoki and Skechers have partnered for a global footwear collaboration. The Skechers tokidoki line launches today and features characters from the tokidoki universe and its heart and crossbones logo across a range of popular Skechers fashion sneakers for women including Skechers Uno.

09:03 EDT Airbnb's Joe Gebbia to step back from full-time operating role - Airbnb made public a note to employees sent by co-founder and Chairman of Airbnb.org Joe Gebbia, which stated in part: "It's been an incredible journey I've joyfully traversed across my 20s, 30s, and now into my 40s. Yet, like any traveler, I often find myself wondering what else there is to explore. After great consideration, I've decided to step back from my full-time operating role at Airbnb... When traveling, we leave a piece of ourselves at every destination, whether they're memories in the lives of people we've met or that one takeout container in the fridge. So I'm excited to continue serving on the Board of Directors of both Airbnb and Airbnb.org. I love and believe in our mission, and don't want to miss out on all the fun, so I will also take on a new role as advisor, supporting Brian, Nate, and the team on the roadmap, future concepts, and our creative culture... The primary reason for this transition is that this is the only company I've ever helped build, and my brain is bursting with more ideas to bring to the world. My first new venture is a startup called parenthood, at which I'll be taking on the role of Dad. The others involve a complementary product to Airbnb, documentary filmmaking, and various philanthropic initiatives. I'm looking forward to sharing more about these with you soon." Reference Link

09:00 EDT 1Life Healthcare trading resumes

08:53 EDT Vicinity Motor announces eligibility in Transport Canada's incentive program - Vicinity Motor announced that its VMC 1200 Class 3 electric trucks have been approved for the Incentives for Medium and Heavy-duty Zero-Emission Vehicles Program administered by Transport Canada, which helps to make buying or leasing zero-emission vehicles more affordable. The iMHZEV Program offers point-of-sale incentives for Canadian organizations and businesses who buy or lease an approved MHZEV. Before including a vehicle on the list of eligible vehicles, Transport Canada reviews an application from the automaker to certify that the vehicle meets the iMHZEV Program requirements. Incentives range from C$10,000 to $200,000 depending on vehicle type. Businesses will have the option to purchase or lease new vehicles under the iMHZEV program, with a maximum of 10 incentives or C$1,000,000 available per calendar year per organization.

08:51 EDT DriveItAway moves headquarters to ic@3401 in Philadelphia - DriveItAway Holdings announced that it has officially become part Philadelphia's growing Innovation District in University City, by moving its headquarters to ic@3401. A partnership between the University City Science Center and Drexel University, ic@3401, is a shared workspace and incubator built around a culture of inclusion, innovation and entrepreneurship, bringing the financial, educational, and human talent focused to rapidly scaling enterprises.

08:50 EDT Newtek Business Services files preliminary proxy statement - Newtek Business Services announced that on July 20, 2022, the Company filed a preliminary proxy statement seeking among other things, shareholder authorization for the Company to sell shares of its common stock at a price below the then current net asset value per share, subject to certain limitations described in the Proxy Statement. The Company has sought such shareholder approval each year the company has been a BDC. The filing of the Proxy Statement does not change the Company's intent to acquire the National Bank of New York City, subject to pending regulatory approvals. Barry Sloane, Chairman, President and CEO said, "At Newtek's June 1, 2022 shareholder meeting, the Company received overwhelming shareholder approval of 89% to withdraw its election as a BDC in connection with the Company's pending agreement to acquire NBNYC, and convert to a bank holding company, subject to regulatory approvals. The regulatory review process is ongoing and while that process is moving forward, the Company will continue to operate as a BDC with the final decision on the timing of our discontinuance from regulation as a BDC to be made by our Board of Directors. In that regard, the Company has filed a Proxy Statement, as it has done in each of the 8 years since its conversion to a BDC in 2014, regarding share issuances. It remains management's intention to move forward and acquire NBNYC and operate as a bank holding company, subject to regulatory approval."

08:49 EDT American Airlines says total debt reduction 'remains a top priority' - Says will keep liquidity at "elevated levels" near-term. Expects $375M of debt repayments in Q3. Expects to take Boeing (BA) 787 deliveries this quarter. Expects to take nine 787s deliveries this quarter, and four in early 2023. Sees Airbus (EADSY) A321XLR deliveries moving to 1Q24 vs. 3Q23.

08:45 EDT AIM ImmunoTech stockholder announces director nominations - Jonathan Jorgl, an AIM ImmunoTech stockholder, together with his nominees, Robert Chioini and Michael Rice announced that Mr. Jorgl delivered notice to AIM on July 8, 2022 of his intent to nominate Mr. Chioini and Mr. Rice to the AIM board of directors - to replace Directors William Mitchell and Stewart Appelrouth. The group said, "Notwithstanding meritless claims to the contrary by AIM, the Notice is valid and complied with AIM's bylaws. As such, the AIM Stockholder Full Value Committee intends to file a preliminary proxy statement with the SEC in due course and solicit proxies for the election of Mr. Chioini and Mr. Rice at AIM's annual meeting of stockholders. In response to the submission of the Notice and the threat of stockholder action to elect two truly independent directors focused on creating real value for all stockholders, AIM's Board issued a press release falsely stating the notice was not valid and commenced frivolous litigation to try and block the valid exercise of the basic stockholder right to elect directors. The press release issued by AIM on July 18, 2022, as well as the complaint filed by AIM in the U.S. District Court for the Middle District of Florida baselessly alleging that the members of the ASFV Committee are acting as a group with certain other stockholders of AIM and/or other individuals, in fact contain false, misleading and irrelevant information with respect to the members of the ASFV Committee and their activities. The allegations in the Florida action are entirely without merit as it relates to the members of the ASFV Committee, and the AIM Stockholder Full Value Committee members will take whatever action is necessary to defend themselves and otherwise to preserve their rights. We believe the incumbent directors' improper rejection of the Notice is not legitimate and is a self-serving attempt to squash stockholder rights and voices by pressuring the AIM Stockholder Full Value Committee to back down, evidenced by their issuance of a press release and commencement of costly and wasteful litigation prior to finally responding to the Notice. These actions by AIM CEO Tom Equels and directors William Mitchell and Stewart Appelrouth are appalling and a waste of stockholder resources, we believe for the primary purpose of entrenching management solely driven by their greed...The AIM Stockholder Value Committee believes strongly that for the sake of stockholders and patients AIM needs new directors who can unlock the value of AIM's lead technology Ampligen by running a successful clinical development program leading to FDA marketing approval and generating sales of the company's FDA approved drug Alferon N Injection, while providing transparency to stockholders and presenting AIM's exciting opportunity to institutional health care funds on Wall Street and other investors, as well as greatly improving corporate governance at the company. As such, the AIM Stockholder Full Value Committee intends to move forward with its campaign to elect new, highly experienced and ethical directors in Mr. Chioini and Mr. Rice, who together will drive value with a sense of urgency for AIM shareholders."

08:42 EDT 1Life Healthcare to resume trading at 9:00 am ET - 1Life Healthcare (ONEM) is set to resume trading at 9:00 am ET, with quotation scheduled to resume at 8:55 am ET, according to Nasdaq. 1Life shares were halted ahead of the announcement that Amazon (AMZN) and One Medical (ONEM) announced that they have entered into a definitive merger agreement under which Amazon will acquire One Medical for $18 per share in an all-cash transaction valued at approximately $3.9B, including One Medical's net debt.

08:41 EDT PharmaCyte Biotech starts 1st phase of two-phase pig study - PharmaCyte Biotech announced that it has commenced the pilot phase of its two-phase pig study. The pig study is the last of several requirements PharmaCyte has complied with related to the requests from the U.S. Food and Drug Administration, FDA, to lift the clinical hold on PharmaCyte's planned Phase 2b clinical trial for locally advanced, inoperable pancreatic cancer, LAPC. PharmaCyte's Chief Executive Officer, Kenneth L. Waggoner, explained, "As part of the Investigational New Drug Application process in preparation for our planned clinical trial in LAPC, the FDA requested data in a large animal, such as a pig, which allows for assessment of safety and distribution of CypCaps following infusion using the clinical route of application, devices, and procedures. "The study will be conducted in two phases. The first phase, which began today, is a short pilot study in two pigs. The objective of this pilot study is to assess microcatheter-based delivery of CypCaps in the pancreatic arterial system. Volume of dose, number of CypCaps, and treatment location will be evaluated using imaging and histology. Also, the CypCaps used in the study will contain radiopaque microspheres, which will be evaluated to track the movement of the CypCaps.

08:40 EDT American Airlines says 'our actions are producing expected results' - Says will limit capacity to resources available. Says while June was challenging, seeing improvement in July. Says plan to return to profitability is working. Comments taken from Q2 earnings conference call.

08:39 EDT AMMO announces launch of Green Streak ammunition - AMMO announces the successful development and launch of its Green Streak patented one-way luminescent ammunition. The Streak is the next generation of visual ammunition featuring one-way luminescent technology, which has been offered by AMMO for a number of years in Red. "Building upon the great success we have had with our Red Streak ammunition in the marketplace, our team has worked to expand our patent on the cutting-edge application process we utilize to apply the patented product to the round, resulting in the grant 18 months ago of additional patent protection," noted Fred Wagenhals, AMMO's Chairman & CEO. "At the same time, our engineering team has been working to develop this Green version of our O.W.L. Technology to offer the Streak rounds in that color variant because green is a top visibility color for the naked human eye. Based upon their hard work, we are excited to roll this color-enhanced product out to the commercial, military and law enforcement markets."

08:36 EDT Freeport-McMoRan increases share repurchase program up to $5B

08:34 EDT Amazon to acquire One Medical for $18 per share in cash - Amazon (AMZN) and One Medical (ONEM) announced that they have entered into a definitive merger agreement under which Amazon will acquire One Medical, a "human-centered, technology-powered national primary care organization on a mission to make quality care more affordable, accessible, and enjoyable through a seamless combination of in-person, digital, and virtual care services." Amazon will acquire One Medical for $18 per share in an all-cash transaction valued at approximately $3.9B, including One Medical's net debt. Completion of the transaction is subject to customary closing conditions, including approval by One Medical's shareholders and regulatory approval. On completion, Amir Dan Rubin will remain as CEO of One Medical. "We think health care is high on the list of experiences that need reinvention. Booking an appointment, waiting weeks or even months to be seen, taking time off work, driving to a clinic, finding a parking spot, waiting in the waiting room then the exam room for what is too often a rushed few minutes with a doctor, then making another trip to a pharmacy - we see lots of opportunity to both improve the quality of the experience and give people back valuable time in their days. We love inventing to make what should be easy easier and we want to be one of the companies that helps dramatically improve the healthcare experience over the next several years. Together with One Medical's human-centered and technology-powered approach to health care, we believe we can and will help more people get better care, when and how they need it. We look forward to delivering on that long-term mission," said Neil Lindsay, SVP of Amazon Health Services.

08:33 EDT Array enters into settlement agreement with Nextracker, Flextronics - Array Technologies and Nextracker, Daniel S. Shugar, Marco Garcia, Flextronics International U.S.A., Scott Graybeal and Colin Mitchell have entered into a monetary settlement agreement to resolve a lawsuit Array filed in 2017 in the United States District Court for the District of New Mexico, Case No. 1:17-cv-00087-JCH-LF. Array's claims in the lawsuit included misappropriation of Array's trade secrets, tortious interference of contract, and breach of contract. The trial was set to begin on Monday, July 18, 2022. Nextracker acknowledges that an Array employee was hired in violation of his non-compete agreement, certain Array confidential information was improperly obtained, and Nextracker's behavior was wrongful. As part of the settlement, the parties agreed to treat the settlement terms as confidential except to the extent required or necessitated by law, regulation, or the corporate parties' shareholder disclosure standards.

08:33 EDT Freeport-McMoRan sees 2022 capital expenditures $3.1B - Sees 2022 copper sales 4.2B lbs., 2023 copper sales 4.45B lbs and 2024 copper sales 4.2B lbs. Sees 2022 gold sales 1.7M ozs, 2023 gold sales 1.7M ozs. and 2024 gold sales 1.6M ozs. Sees 2022 molybdenum sales 80M lbs., 2023 molybdenum sales 80M lbs. and 2024 molybdenum sales 80M lbs. Sees 2023 Capex $3.1B. Comments taken from presentation slides for Q2 earnings conference call.

08:33 EDT Vistra names Kris Moldovan as CFO, effective August 1 - Vistra announced that its board of directors has appointed company veteran Kris Moldovan as its next CFO, effective August 1. Moldovan assumes the CFO role from Jim Burke, who, as previously announced, will transition to CEO on August 1. Moldovan's appointment marks the completion of Vistra's search process. Moldovan has been with Vistra and its predecessor companies since 2006 and, for the past five years, has served as senior vice president and treasurer, where he is responsible for all treasury-related activities, including financing activities and assuring availability of liquidity and cash resources, among other responsibilities. From 2010 to 2017, he was the company's assistant treasurer.

08:32 EDT Amazon to acquire One Medical for $18 per share in cash

08:31 EDT Anixa Biosciences reports notice of allowance of additional patent - Anixa Biosciences announced that the U.S. Patent and Trademark Office has issued a Notice of Allowance broadening protection of Anixa's novel breast cancer vaccine technology, which has been exclusively licensed from, and is being developed in partnership with, Cleveland Clinic. The patent is titled, "Breast Cancer Vaccine," and the lead inventor is Dr. Vincent Tuohy of the Department of Inflammation and Immunity at Cleveland Clinic's Lerner Research Institute. This patent is in the family of the originally granted patent, and it covers additional intellectual property related to Anixa's breast cancer vaccine technology. "We are pleased to receive this notice of allowance from the USPTO, confirming additional protection of the breast cancer vaccine technology," stated Dr. Amit Kumar, Chairman and CEO of Anixa.

08:27 EDT 1Life Healthcare trading halted, news pending

08:22 EDT Agco names Tim Millwood as Chief Supply Chain succeeding Hans-Bernd Veltmaat - AGCO (AGCO) announced that its Board of Directors has appointed Tim Millwood to succeed Hans-Bernd Veltmaat as Senior Vice President and Chief Supply Chain Officer effective August 15. Mr. Millwood joins AGCO following a more than thirty-year career at Cummins (CMI), a global power technology leader, where he most recently served as Vice President, Global Manufacturing.

08:18 EDT Sangamo gets EC OMPD to CAR-Treg cell therapy TX200 for organ transplantation - Sangamo Therapeutics announced that the European Commission has granted Orphan Medicinal Product Designation, OMPD, to TX200, a wholly-owned autologous Chimeric Antigen Receptor Regulatory T Cell or CAR-Treg cell therapy product candidate for treatment in solid organ transplantation. "Patients who have received a solid organ transplant require lifelong surveillance and chronic immunosuppressive medications to manage the risk of transplant rejection," said Rob Schott, MD, MPH, FACC, Head of Development for Sangamo. "Our goal with TX200 is to create a transformative therapy that reduces the risk of organ rejection, while reducing the patient burden from chronic immunosuppressive therapy. Achieving this important regulatory milestone takes us one step closer to realizing that goal for patients." Dosing of the first patient in the STEADFAST Phase 1/2 clinical study took place in March 2022, with the second patient dosing planned later this quarter. The EC granted OMPD to TX200 following a positive opinion from the European Medicines Agency's Committee for Orphan Medicinal Products. To qualify for orphan designation, a treatment must be intended for a life-threatening or chronically debilitating disease affecting fewer than 5 in 10,000 people. Importantly, no satisfactory method of treatment must exist, or if such a method exists, the treatment must be of significant benefit to patients. The OMPD status offers a range of incentives to encourage the development of orphan medicines, including protocol assistance on study protocols, potential fee reductions, and 10 years of market exclusivity upon regulatory approval.

08:17 EDT Herborium Group eliminates $200,000 in corporate debts - Herborium Group announced the following accomplishments for the first half of 2022. The Company also shares with Investors the plan for the remaining months of the year. According to prior announced plans, the Company eliminated $200,000 in corporate debts without dilutive financing or issuing additional corporate shares. The Company will continue its efforts to reduce debt without dilution, possibly retire shares and to increase shareholders value. The Company stayed current and maintained the Highest Tier of Reporting on OTC. Almost 2000 companies were eliminated from OTC for lack of regulatory compliance and reporting. Despite inflationary pressure and other disadvantageous economic factors the Company maintains strong sales during the entire six month period. Herborium improved its margins from 61% of 64% and developed some new business alliances. These alliances are expected to be monetized during the next 6-12 months. During the past six months, the company accelerated its transformation from an Acne Treatment Company to become an interactive, AI based platform for integrated product, content and expertise in the area or skincare: The introduction of the first stage of SKIN-NATURA(R) is expected in the 4th Quarter of 2022. With a strong global trend towards using natural products, with a 21% growth in on online beauty business since 2018 and over 75% of women and over 55% of men purchasing their selfcare products online, Herborium's expansion of its platform opens new growth opportunities for the Company. Due to Herborium's unique expertise, the new platform will provide all needed deliverables for consumers and professionals seeking natural alternatives to serious self-care concerns unanswered by traditional providers. This innovative technology platform will allow the Company to establish a Consortium of preselected natural products and know-how partners that together provide one of a kind, comprehensive, easy to use and friendly to access one stop shopping for personalized selfcare products. In addition, regimens, treatment options, counseling, advisement, medical and nutritional assistance and a curated consumer forum in the natural wellness and beauty space will be provided. This new business model will allow Herborium to realize multiple revenue streams, significantly expand its market reach, increase consumer satisfaction and loyalty as well as create additional shareholders value through revenue growth and increased brand recognition. This initiative will also provide potential for further partnerships and acquisitions.

08:15 EDT Aqua Metals enters non-binding LOI to supply lithium hydroxide to Dragonfly - Aqua Metals and Dragonfly Energy Corporation, a leading manufacturer of deep-cycle lithium-ion batteries, announce they have entered into a non-binding letter of intent, LOI, for Aqua Metals to supply lithium hydroxide to Dragonfly. Under the LOI, Dragonfly would purchase commercial quantities of lithium hydroxide from Aqua Metals to support Dragonfly's ongoing development of its solid state lithium-ion battery technologies and future manufacturing activities, as well as providing recycling services. Dragonfly expects to begin production of its solid-state pilot line in 2023, with a supply of lithium hydroxide from Aqua Metals to commence at the time of full-scale manufacturing. "Aqua Metals continues to develop what we believe is the cleanest and most cost-efficient lithium-ion battery recycling solution that is fundamentally non-polluting," said Steve Cotton, President and CEO of Aqua Metals. "We are pleased to partner with Dragonfly Energy, a cutting edge company that recognizes our superior, high-value lithium recovery approach with the lowest environmental footprint of any technology currently under development."

08:14 EDT 180 Life Sciences announces closing of $6.5M registered direct offering - 180 Life Sciences announced the closing of its previously-announced registered direct offering to a single healthcare-focused U.S. institutional investor of 6,132,076 shares of the Company's common stock and warrants to purchase up to 6,132,076 shares of common stock at a purchase price per share of $1.06. The warrants have an exercise price of $1.06 per share, are initially exercisable beginning six months following the date of issuance and expire five years from the initial exercise date. The Company intends to use the net proceeds from the offering for research and development expenses and general corporate purposes. A.G.P./Alliance Global Partners acted as the sole placement agent for the offering.

08:13 EDT Bionano announces publication of new study using OGM on iPSC lines - Bionano Genomics announced publication of a study using optical genome mapping, OGM, to investigate numerical and structural changes to two induced pluripotent stem cell, iPSC, lines, WTC-11 and Tuba1-GFP, during long-term culturing. This research provides scientific and practical support for the use of OGM workflows in regenerative medicine due to OGM's ability to detect hundreds of structural variants, SVs, many of which had not been seen by other cytogenetic methods and which may impact the genomic integrity of iPSCs. In the study, published in Genes, the authors followed two cell lines over 150 days of continuous culture, or 50 passages, and found significant changes to the genome in both using OGM. Additionally, hundreds of SVs not found in the internal control database were also observed in both cell lines and accumulated over the course of the study, potentially impacting gene expression and cell survival. The authors also suggest that, because of the accumulation of chromosome changes over time and the unknown effects on iPSCs in therapy, culture times should be limited. "Bionano is expanding into markets where OGM is an alternative workflow for cytogenetics in genetic diseases and cancer. In addition, we are driving adoption of OGM into the academic research community to enable novel discoveries connected to structural variations. This paper outlines the utility of OGM for pharmaceutical research and drug development, which is a segment of the genomics market that Bionano is also targeting," commented Erik Holmlin, PhD, president and chief executive officer of Bionano Genomics.

08:11 EDT Daxor partners with MedAxiom for BVA-100 adoption - Daxor Corporation announces it has entered into an industry partnership with MedAxiom, an American College of Cardiology company, to amplify awareness and adoption of Daxor's blood volume analysis technology to achieve healthcare's Quadruple Aim of better outcomes, lower costs, improved patient experience and improved clinician experience.

08:10 EDT Ford not spinning off Model e, says CEO Farley

08:11 EDT Splash Beverage announces agreement with UNFI to distribute TapouT drinks - Splash Beverage (SBEV) announced that it has signed a distribution agreement with United Natural Foods (UNFI) to distribute TapouT Performance drinks through Southeastern Grocer's 515 Winn Dixie stores located throughout the southeastern United States and other areas where TapouT does not have Direct Store Distribution, DSD, coverage. "We are absolutely thrilled to have reached an agreement with UNFI to distribute TapouT through its network. UNFI's authorization of TapouT is a testament to its all-natural ingredients and clean label. UNFI maintains high standards resulting from their massive natural-foods customer base. The initial 515 Winn Dixie stores represent a significant increase in our distribution reach and opens the door to significantly more UNFI locations, both natural grocery chains and traditional retail locations. This provides needed incremental distribution coverage to the DSD network we're building throughout the US. This is a major milestone in our strategic growth plan and gives us an advantage over the competition as we can now start to penetrate the natural food channel in earnest."

08:09 EDT Ford targeting annual production of 2M EVs by 2026, says CEO Farley - Comments taken from Ford's conference call discussing its new battery capacity plan.

08:09 EDT VVC portfolio company Proton Green plans for 'reverse merger' with Schmitt - VVC Exploration Corporation announces that Proton Green, LLC. has entered into a non-binding term sheet which contemplates the reverse merger with Schmitt Industries. VVC is a founding shareholder of Proton Green, which launched in 2021 and currently owns approximately 14% of Proton Green. Highlights: Proton Green, led by Steve Looper, a former VVC team member, is one of the leading helium and hydrogen production and carbon sequestration hubs in North America. As a founding shareholder, VVC currently owns 13.97% of Proton Green. Proton Green was founded in 2021 based on the potential of the St. John's Field which contains 33 billion cubic feet of helium based on an independent third-party report. Under the merger agreement with Schmitt, Proton Green would own 95% of the combined company. The Company would be renamed 'Proton Green Corporation' and the common stock would continue to trade on the Nasdaq under a new symbol.

08:08 EDT Verizon Business, VIT reach agreement for private 5G network - Verizon Business and Virginia International Terminals announced an agreement to build a private 5G Ultra Wideband network at one of The Port Of Virginia's main container terminals. Virginia International Terminals, VIT, is a privately held terminal operating company that is owned by the Virginia Port Authority, which is an agency of the state of Virginia. The deal is Verizon Business' second with a major international port and its first with a U.S.-based terminal. "Seaports provide some of the best possible examples of the power of private 5G, with uses spanning autonomous vehicles, connected heavy equipment, and secure, real-time tracking and logistics, among many others," said Sowmyanarayan Sampath, CEO of Verizon Business. "That's why On Site 5G is ideal for innovative partners like Virginia International Terminals. It puts a wide range of 5G capabilities on offer, from data-intensive, high-bandwidth industrial needs to secure, reliable broadband for everyday business." In the recently closed fiscal year, VIT handled 3.7M TEUs and accounted for approximately $47B in gross product for the state. VIT recently received a U.S. Department of Transportation grant to create a proof of concept for autonomous over-the-road trucks, bringing together experts from industry and academia to devise a solution for this critical logistics chain need. Private 5G is a critical component to the solution being developed.

08:06 EDT Victory Square Technologies reports NAV $89,704,469 as of June 30 - Victory Square Technologies is pleased to provide a Corporate Update. Shafin Diamond Tejani, CEO of Victory Square: "I want to personally thank all of Victory Square's shareholders that have believed in our mission and vision. We've been very fortunate to have such a passionate, supportive and vocal shareholder base. Despite market conditions, our team is committed to building long-term shareholder value. As we recently entered Q3 2022, I'd like to take this opportunity to share some notable highlights from Q2 2022." Net Asset Value unaudited June 30th, 2022 Update: NAV - $89,704,469 approx.

08:05 EDT Computer Services increases quarterly cash dividend to 29c per share - Computer Services announced that its board of directors increased the quarterly cash dividend to 29c per share. The dividend is payable on September 26 to shareholders of record as of the close of business on September 1.

08:04 EDT Wyndham Hotels & Resorts, Palladium Hotel sign strategic alliance - Wyndham Hotels & Resorts and Palladium Hotel Group a commercial alliance that will add more than 6,500 rooms to Wyndham's Registry Collection. The 14 spectacular all-inclusive TRS Hotels and Grand Palladium Hotels & Resorts managed by Palladium Hotel Group are located in Mexico, Dominican Republic, Jamaica, and Brazil and will join Wyndham's portfolio under a long-term agreement leveraging Wyndham's extensive distribution and bringing Wyndham's all-inclusive resort portfolio to 26 hotels.

08:04 EDT Pliant receives FDA Fast Track designation for PLN-74809 for treating PSC - Pliant Therapeutics has received Fast Track designation from the U.S. Food and Drug Administration, FDA, for the potential treatment of primary sclerosing cholangitis, PSC. PLN-74809, the Company's lead drug candidate, is currently being tested as part of the INTEGRIS-PSC Phase 2a clinical trial. Pliant anticipates topline data from this randomized, double-blind, placebo-controlled trial in patients with PSC, in the first half of 2023. "Fast Track designation in primary sclerosing cholangitis represents a significant milestone in PLN-74809's development," said Eric Lefebvre, M.D., Chief Medical Officer at Pliant Therapeutics. "PSC is a deadly disease with no FDA-approved Therapies. Fast Track designation underscores the urgent need for new therapeutic options to address PSC and other fibrotic diseases."

08:03 EDT First Solar to supply Solarvest Holdings with 93 MW for Malaysian projects - First Solar will supply Solarvest Holdings Berhad, a clean energy specialist and turnkey engineering, procurement, construction and commissioning service provider in South-East Asia, with 93 megawatts DC of advanced thin film photovoltaic solar panels. The modules will power four projects being built as part of Malaysia's Large Scale Solar Program with deliveries taking place between August to November, 2022. Solarvest will use First Solar Series 6 modules for projects located in the Malaysian states of Selangor, Perak, and Kedah. Approximately 75 MW of the total order is expected to be sourced from First Solar's manufacturing facility in Kulim, Malaysia.

08:02 EDT Nucor sees 'strong quarter of profitability' in Q3 - Nucor said: "As we enter the third quarter, demand remains stable and resilient across the major end-use markets we serve, and customer inventory levels appear right-sized relative to economic conditions. Though we expect a decrease from the record-setting second quarter, we expect another strong quarter of profitability in the third quarter of 2022. We believe that 2022 will be the most profitable year in Nucor's history. We expect the steel mills segment earnings to be sequentially lower in the third quarter of 2022, due to lower expected shipment volumes and average selling prices, particularly at our sheet and plate mills. The steel products segment is expected to have another very strong quarter in the third quarter of 2022, with earnings roughly in-line with the second quarter of 2022. Raw materials segment earnings are expected to improve in the third quarter of 2022 due to higher realized pricing at our DRI facilities."

07:58 EDT A2Z Smart Technologies expands Accenture relationship - A2Z Smart Technologies announced that, in conjunction with its strategic partnership with Accenture, the Company's smart carts are now showcased at the Accenture Custom Innovation Network, the largest Accenture showcase facility in Europe, in Milan, Italy.

07:57 EDT Incannex approved to commence Phase 1 clinical trial of IHL-675A - Incannex Healthcare is pleased to announce that it has received approval from the Bellberry Human Research Ethics Committee for a phase 1 clinical trial investigating its proprietary multi-use, anti-inflammatory drug IHL-675A. The trial will be conducted at CMAX Clinical Research in Adelaide, South Australia, and managed by Avance Clinical. Patient recruitment is anticipated to commence in August.

07:56 EDT Auddia's faidr mobile app receives over 80,000 downloads in Q2 - Auddia announced that in Q2 of 2022, its flagship faidr mobile app exceeded its target goals, receiving more than 80,000 downloads, achieving a cost-per-install of less than $3, and surpassing 40,000 monthly active users. "The goal of our initial marketing effort for faidr was twofold. First, we wanted to demonstrate that consumers were interested in downloading an app that gives them control over the radio listening experience, and second, we wanted to build an audience that we could leverage to see how consumers use faidr. Real world usage data is invaluable for optimizing the user experience, which is a prerequisite for driving the highest possible subscription-conversion metrics," said Auddia CEO Michael Lawless. "We were encouraged by the 90-day launch results we provided for faidr in mid-May and are further encouraged by the final Q2 results of this initial marketing push. We far exceeded our initial targets for downloads, cost-per-install, and MAU's." The Company is now focused on an iterative process of analyzing user behavior in the app, using that data to prioritize product enhancements, and analyzing the consumer response to those product changes. This process is already yielding solid improvements in key usage statistics, and management is encouraged that this optimization process will result in user engagement and subscription conversion metrics that are comparable, or superior, to the early subscription conversion rates reported by other media app category leaders. The Company, in conjunction with the process of optimizing usage data through product enhancements, will conduct a series of subscription trials with its existing user base in preparation for announcing initial subscription conversion rates and 2023 revenue guidance at the time of filing its third quarter 10Q.

07:50 EDT Union Pacific backs FY22 CapEx view $3.3B - Affirmed: Pricing gains in excess of inflation dollars; Capital spending of $3.3B; Long term dividend payout target of 45% of earnings; Share repurchases in line with 2021.

07:47 EDT Union Pacific CEO says Q2 'was a tough one' - "As anticipated, the Second Quarter was a tough one as we limited carloadings and increased expenses to recover network fluidity," said Lance Fritz, Union Pacific chairman, president, and CEO. "We also experienced record high fuel prices and increasing inflation, adding pressure to our total costs. Offsetting the cost pressures were higher fuel surcharge revenue, solid core pricing, a positive mix, and continued train size initiatives. The result was operating revenue and income growth. Our network fluidity improved through the quarter, and we are positioned to grow volumes in the back half of 2022 while continuing to improve our service product."

07:46 EDT Jacobs to deliver major redevelopment for hospital and health precinct - Jacobs was named by New South Wales Health Infrastructure as lead architect and principal design consultant for stage three of the St George Hospital and Community Health Services campus redevelopment. This work will deliver a new Integrated Ambulatory Care Precinct, providing improved capacity and capability to treat a growing and aging multicultural population managing chronic and complex diseases, the company said.The NSW government is investing $282M to build the new precinct and improve parking facilities on site and is on track to be completed in 2025.

07:44 EDT Osino closes Ondundu acquisition from B2Gold through shares issuance - Osino Resources (OSIIF) announces that the Company has completed its acquisition yesterday from B2Gold Corp. (BTG) of the Ondundu gold exploration property in Namibia under the Acquisition Agreement dated December 31, 2021, as amended June 28, 2022 and July 18, 2022, and as described in the Company's news releases dated January 6, 2022 and June 28, 2022. Pursuant to the Acquisition Agreement, the Company issued 11,630,628 common shares of Osino to B2Gold to satisfy aggregate consideration of $8,850,000 to acquire all of the issued and outstanding shares of the Namibian company, Razorback Gold Mining Company Limited, which owns 100% of the Namibian exclusive prospecting license 3195 covering 19,969 hectares located approximately 130km northwest of Osino's Twin Hills Gold Project in Namibia, together with all technical information and other books and records in respect thereof. Under the Acquisition Agreement, the remaining $6,350,000 of the aggregate $15,200,000 purchase price may also be settled through more shares in lieu of cash. Heye Daun, Osino's President and CEO, commented, "We are very pleased to have closed the acquisition of the Ondundu Gold Project. B2Gold's partnership in this process and their agreement to accept Osino shares instead of cash to purchase the Project will enable us to comfortably execute our development plans while maintaining a prudent financial position in a challenging market environment. We are on track to publish a maiden resource for Ondundu after the publication of the Twin Hills PFS and confirmatory metallurgical testwork is ongoing. Osino's vision for Ondundu is to demonstrate a feasible mining and process route involving gravity pre-concentration at Ondundu with subsequent leaching and further processing at Twin Hills. We therefore feel confident in the additional value Ondundu brings to our portfolio and look forward to providing further updates in due course."

07:42 EDT Electrovaya announces increase in credit facility to C$16M - Electrovaya announced that its credit facility has been increased from C$14M to C$16M to support its sales growth. As consideration for these amendments, Electrovaya has paid a fee of C$50,000, paid in shares to the financial institution.

07:42 EDT Sonnet BioTherapeutics announces trial of SON-1010 in healthy volunteers - Sonnet BioTherapeutics announced that a second Phase 1 clinical trial of SON-1010 has been authorized to begin, based on the successful initiation of the first two cohorts in the first-in-human dose-escalation trial in patients with advanced solid tumors. This new study, being conducted in healthy volunteers in Australia, is a single ascending dose-escalation trial designed to provide extensive additional pharmacokinetic, pharmacodynamic and cell response data with SON-1010. Importantly, SB102 is expected to inform Sonnet's decisions about pursuing additional indications of interest with SON-1010, as well as augmenting the foundational work underway with the company's bispecific molecules. SON-1010 is a proprietary version of recombinant human Interleukin 12, configured using the FHAB technology that targets tumor and lymphatictissue, providing a mechanism for dose sparing due to its extended PK properties. The extension of PK with the FHAB platform may improve the safety and efficacy profile of IL-12, an effect that can be complemented using a variety of potent immuno modulators that will be linked to the molecule in a bispecific construct in subsequent programs.

07:41 EDT Ford collaborates with mining companies to source Nickel through 2026 - Ford (F) also announced it is working with major mining collaborators and has sourced most of the nickel needed through 2026 and beyond. Ford has signed non-binding MOUs with: Vale Canada to explore potential opportunities across the EV value chain; PT Vale Indonesia and Huayou Cobalt for exploring a three-way nickel processing project and, separately, an off-take agreement with Huayou that collectively will provide Ford with rights to the equivalent of 84 kilotons per annum of nickel; BHP (BHP) for nickel supply from BHP's Nickel West operations in Australia. The targeted multi-year agreement could start as early as 2025 and may involve additional commodities over time. Ford also has locked several key lithium contracts. Beyond the recently announced key asset in Western Australia secured through Liontown Resources, Ford also has signed a non-binding MOU with Rio Tinto (RIO), exploring a significant lithium off-take agreement from its Rincon project in Argentina. This is part of a multi-metal MOU that leverages the scale of Ford's aluminum business and includes a potential opportunity on copper. Ford also continues working to localize processing of key battery materials in North America. To that end, the company is announcing that EcoPro BM and SK On have signed a non-binding letter of intent with Ford to establish a cathode production facility in North America. Pioneer has signed a binding off-take agreement with Ford for lithium carbonate from ioneer's Rhyolite Ridge project in Nevada to support EV production beyond 2025. Compass Minerals (CMP) has signed a non-binding MOU for lithium hydroxide and lithium carbonate from its Utah operations on the Great Salt Lake. Syrah Resources and SK On have signed a non-binding MOU to secure off-take for natural graphite from its processing site in Vidalia, Louisiana. As Ford reinvents its new EV supply chain, consumer praise rolls in for its first-generation EVs already in-market while demand signals among potential EV buyers continue strengthening. For the first time, the majority of consumers who intend to buy a car in the next two years say they will choose an EV or hybrid vehicle, up 11% from last year and 22% from 2020, according to research published by EY. Most of that increase is for full EVs. Among commercial owners who don't already deploy EVs, 60% of U.S. fleet managers said in a Ford Pro survey they plan to add EVs to their operations within two years.

07:39 EDT Rio and Tinto Ford sign MOU for battery and low carbon materials supply chain - Ford Motor Company and Rio Tinto have signed a non-binding global memorandum of understanding MOU to jointly develop more sustainable and secure supply chains for battery and low-carbon materials to be used in Ford vehicles. The multi-materials partnership will support the transition toward a net-zero future by supplying Ford, one of the world's largest automakers, with materials including lithium, low-carbon aluminium and copper. It will allow Rio Tinto, a leading global mining and metals company, to progress its commitment to work with customers to decarbonise value chains. Under the agreement, Ford will explore becoming the foundation customer for Rio Tinto's Rincon lithium project in Argentina. Rio Tinto is currently progressing detailed planning to bring Rincon into production and will work with Ford toward a significant lithium off-take agreement to support its production of electric vehicles. The companies will work together to strengthen the supply of low carbon aluminium for use in Ford vehicles, including metal produced using the zero carbon ELYSIS smelting technology and from Rio Tinto's hydro-powered operations in Canada, helping Ford meet its commitment to the First Mover's Coalition.

07:37 EDT Field Trip Health announces first dosings in Phase 1 clinical study of FT-104 - Field Trip Health announcedthe first successful dosings in the Phase 1 Clinical Study entitled "A Double-Blind, Randomized, Placebo-Controlled Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Single, Ascending, Subcutaneous Doses of FT-104 HCl In Healthy Volunteers." The study is being conducted at PARC Clinical Research at the Royal Adelaide Hospital in Australia. Field Trip's first molecule in development, FT-104, is a prodrug of 4-OH-DiPT, a synthetic serotonin-2A agonist. Pre-clinical data suggests FT-104 has a potency and pharmacology similar to psilocybin, but with a significantly shorter half-life of approximately three hours. Based on the FT-104 pre-clinical profile projecting a reduced treatment burden, and promising results from the early psilocybin therapy studies1 conducted at leading academic centers, the Company believes that FT-104 could provide a rapid, safe and effective therapy for depression and other mental health conditions when delivered in conjunction with psychotherapy. The key objectives of the Phase 1 study include characterization of the safety, tolerability, pharmacokinetics and pharmacodynamic effects of FT-104 over a range of doses. Subjective measurements will include intensity, duration and feelings produced by the acute psychoactivity after administration of FT-104 or placebo. The Company anticipates reporting results from the study in Q4-2022. Dr. Nathan Bryson, Field Trip's Chief Scientific Officer, commented, "The first administration of a novel, proprietary molecule is a landmark step for our Company and a key milestone in our progress to develop FT-104 as a therapeutic for depression. Already, we are planning to share our work and our vision on the development of FT-104 in treatment-resistant depression and postpartum depression with the FDA in order to obtain their guidance as we look toward Phase 2 studies in 2023."

07:36 EDT Ford announces new battery capacity plan, raw materials plan to scale EVs - Ford announced a series of initiatives for sourcing battery capacity and raw materials that light a clear path to reach its targeted annual run rate of 600,000 electric vehicles by late 2023 and more than 2M by the end of 2026. The company detailed its global vehicle portfolio plans supporting these production goals as part of its Ford+ plan. Ford expects a compound annual growth rate for EVs to exceed 90% through 2026, more than double forecasted global industry growth. Ford plans to invest over $50B in EVs through 2026, targeting total company adjusted EBIT margins of 10% and 8% EBIT margins for EVs by 2026. The company continues to plan for more than half its global production to be EVs by 2030 and achieving carbon neutrality globally no later than 2050. Ford plans to reach a 600,000 global EV run rate by late 2023 with the following EVs: 270,000 Mustang Mach-Es for North America, Europe and China; 150,000 F-150 Lightnings for North America; 150,000 Transit EVs for North America and Europe, and 30,000 units of an all-new SUV for Europe, whose run rate will significantly ramp in 2024. Ford is adding lithium iron phosphate cell chemistry to its portfolio, alongside its existing nickel cobalt manganese chemistry. This creates even more capacity for high-demand products and provides customers many years of operation with minimal range loss. It also reduces the reliance on scarce critical minerals such as nickel and, at current costs, brings a 10% to 15% bill of material savings for Ford versus NCM batteries. The company confirmed it has secured 100% of the annual battery cell capacity needed - 60 gigawatt hours- to support this 600,000 EV run rate by working with leading battery companies around the globe. Ford announced that Contemporary Amperex Technology, or CATL, will provide full LFP battery packs for Mustang Mach-E models for North America starting next year as well as F-150 Lightings in early 2024. Ford's EV architecture flexibility allows efficient incorporation of CATL's prismatic LFP cell-to-pack technology, delivering incremental capacity quickly to scale and meet customer demand. Ford also is leveraging its long-standing connection with LG Energy Solution and its strategic relationship with SK On to meet its battery capacity target for late 2023. Long-time supplier LGES has scaled quickly and doubled its capacity at its Wroclaw, Poland, facility to support incremental NCM cell production for Mustang Mach-E and E-Transit models. Plus, SK On has installed capacity to support the scaling of Ford's high-volume F-150 Lightning and E-Transits through late 2023 - scaling NCM cell production beyond earlier-planned levels from its Atlanta facility and providing new battery cell capacity from its Hungary operation. The company now has sourced approximately 70% of the battery cell capacity it needs to support an annual global run rate of more than 2 million EVs by late 2026. Ford and CATL have signed a separate non-binding MOU to explore a cooperation for supplying batteries in Ford's markets across China, Europe and North America. Ford also announced it plans to localize and use 40 GWh of LFP capacity in North America starting in 2026. The company intends to use this additional capacity to complement three previously announced battery plants in Kentucky and Tennessee that are part of the BlueOval SK joint venture between Ford and SK On, which was officially formed last week. Ford has signed an additional MOU with SK On as well as Koc Holdings to create a joint venture in Turkey for expanded battery capacity there. To support its joint ventures, Ford is direct-sourcing battery cell raw materials as well.

07:34 EDT BridgeBio announces founding affiliation with Bakar Labs - BridgeBio Pharma announced its founding affiliation with Bakar Labs, the incubator at UC Berkeley's Bakar BioEnginuity Hub. Bakar Labs was established by the University of California, UC, Berkeley and QB3, "Partnering with UC Berkeley and QB3 to launch Bakar Labs is a natural extension of our mission to discover, create, test, and deliver transformative medicines to as many patients as possible. Through this collaboration, we aim to strengthen the Bay Area biotech ecosystem and potentially unlock new therapies for patients with unmet needs," said BridgeBio founder and CEO Neil Kumar, Ph.D.

07:32 EDT Domino's Pizza still sees FY22 CapEx $120M - Sees food basket pricing up 13%-15% vs. FY21.

07:31 EDT Olema Oncology receives FDA fast track designation for OP-1250 - Olema Pharmaceuticals announced that the U.S. Food and Drug Administration, FDA, has granted Fast Track designation to OP-1250, the Company's novel, oral complete estrogen receptor antagonist and selective ER degrader, for the treatment of ER-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer that has progressed following one or more lines of endocrine therapy with at least one line given in combination with a cyclin-dependent kinase 4/6 inhibitor. OP-1250 is currently being evaluated as a single agent in an ongoing Phase 1/2 clinical trial and in Phase 1b combination with palbociclib in patients with recurrent, locally advanced, or metastatic ER+/HER2- breast cancer. "Receiving Fast Track designation from the FDA for OP-1250 is an important milestone for the development program and underscores OP-1250's potential clinical utility to address a significant unmet medical need in women living with advanced ER+/HER2- breast cancer," said Sean P. Bohen, M.D., Ph.D., President and Chief Executive Officer of Olema Oncology. "We look forward to working closely with the FDA to optimize and expedite the development program, with the goal of making OP-1250 available to patients sooner."

07:25 EDT Huntington Bancshares sees Q4 average loans up high single digits ex-PPP - Sees Q4 NII up high teens to low 20s ex-PPP, ex-PAA, with noninterest income up low to mid single digits. Sees Q4 core expenses up modestly vs. Q2. Comments taken from Q2 earnings conference call presentation slides.

07:17 EDT NeoGenomics appoints Chris Smith as CEO - NeoGenomics announced that Chris Smith has been appointed CEO and a member of the board of directors effective August 15, 2022. Concurrently, Chair of the Board and Interim CEO Lynn Tetrault will resume her role as independent Chair of the Board while assisting in the transition of responsibilities. Smith will join NeoGenomics after serving as CEO of Ortho Clinical Diagnostics from 2019 to May 2022.

07:15 EDT In8bio announces issuance of European patent covering matter for DRI platform - IN8bio announced the issuance of an additional European patent covering the composition of matter for IN8bio's Drug Resistant Immunotherapy, DRI, platform. The patent broadens the Company's intellectual property coverage of genetically engineered innate immune cells beyond gamma-delta T cells to include NK cells. Like gamma-delta T cells, NK cells respond directly to cellular stress and have shown promise in cellular therapy clinical trials. This newly issued patent bolsters the broad global patent portfolio that IN8bio has developed to support its core technology of chemotherapy resistance to enhance the efficacy of cellular therapies against solid tumor cancers. "Our previously issued patents in the United States and Europe broadly cover any genetic engineering that conveys chemotherapy resistance to gamma-delta T cells. This European patent expands our coverage to include NK cells, the other innate immune effectors that can respond to upregulated cellular stress to directly kill tumor cells," said William Ho, CEO and co-founder of IN8bio. "Our unique DRI approach provides the ability to upregulate multiple NKG2D-ligands on the tumor cell surface, which allows for the targeting of heterogenous solid tumor cancers by innate immune cells." The European patent, titled "Drug Resistant Immunotherapy for Treatment of a Cancer", provides additional coverage for the DRI-based approach to cell engineering. Specifically, the patent covers the composition and use of DRI NK cells in oncology. This patent is part of a larger family of intellectual property that has been globally prosecuted by IN8bio, which continues to expand this portfolio and advance a pipeline of novel cellular therapy approaches for the treatment of cancer. These patents are co-owned by and exclusively licensed to IN8bio from the University of Alabama at Birmingham, Children's Healthcare of Atlanta and Emory University.

07:14 EDT Freeline announces NEJM published data on FLT180a - Freeline Therapeutics announced that the New England Journal of Medicine, NEJM, published positive data that expand upon previously announced long-term follow-up data for up to 3.5 years from the Phase 1/2 dose-finding B-AMAZE trial of the company's AAVS3 gene therapy candidate, FLT180a, for people with hemophilia B, a debilitating inherited bleeding disorder caused by a deficiency in coagulation factor IX. "The B-AMAZE long-term data continue to support our confidence that a single dose of FLT180a could protect people with hemophilia B from bleeding and the need for lifelong FIX replacement through durable expression of FIX at protective levels," said Pamela Foulds, MD, Chief Medical Officer of Freeline. Key findings published today in the NEJM article "Phase 1-2 Trial of AAVS3 Gene Therapy in Patients with Hemophilia B" by Pratima Chowdary et al. include: All patients had dose-dependent increases in FIX levels following treatment with FLT180a; At the last follow up, five patients had FIX levels in the normal range, three patients had levels ranging from 23% to 43%, and one high-dose patient was at 260%; The mean annualized bleeding rate across all patients decreased from 2.93 events/year at baseline to 0.71 events/year after treatment with FLT180a; The mean annualized FIX consumption per patient decreased from 226,026 IU/year at baseline to 9,723 IU/year; Treatment was generally well tolerated, with transient transaminitis being the most common FLT180a-related adverse event. No patient discontinued infusion or withdrew from the study. No infusion reactions occurred, and no inhibitors to FIX were detected.

07:13 EDT NeoGenomics names Chris Smith CEO - NeoGenomics announced that industry veteran Chris Smith has been appointed Chief Executive Officer and a member of the board of directors effective August 15 . Concurrently, Chair of the Board and Interim CEO Lynn Tetrault will resume her role as independent Chair of the Board while assisting in the transition of responsibilities. "We are thrilled that Chris has agreed to join NeoGenomics as CEO. The other directors and I are confident that he is the right person to lead our company moving forward. Chris is a remarkable leader with strong cultural values, diagnostic industry experience, and an extensive history of operating success. Chris will be an excellent addition to our talented management team." said Lynn Tetrault, NeoGenomics' Chair of the Board and Interim Chief Executive Officer.Mr. Smith will join NeoGenomics after serving as CEO of Ortho Clinical Diagnostics from 2019 to May 2022.

07:12 EDT Genius Group appoints Erez Simha as CFO - Genius Group announced the appointment of Erez Simha as its CFO. He has been appointed in this role to help accelerate the company's global growth. Simha brings over 20 years of experience and a proven track record of scaling companies in multiple industries.

07:10 EDT Philip Morris expects Swedish Match transaction to close in fourth quarter - On May 11, Philip Morris Holland Holdings B.V., an affiliate of PMI, announced a recommended public offer to the shareholders of Swedish Match AB to tender all shares in Swedish Match, excluding treasury shares, to PMHH at a price of SEK 106 in cash per share. On June 28, the offer document regarding PMHH's recommended offer was made public, following approval and registration by the Swedish Financial Supervisory Authority. PMI expects the transaction to close in the fourth quarter of this year, subject to Swedish Match shareholder acceptance and all necessary regulatory and other approvals. As of the date of the offer document, the waiting period for the transaction under the U.S. Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, had expired, meaning that PMHH has satisfied its requirements under the HSR Act to proceed with the transaction, PMI stated.

07:09 EDT BitNile unit to supply Aero Corporation with DC Fast chargers - BitNile Holdings announced that its green energy technology and power supply subsidiary, TurnOnGreen, will supply the electric vehicle charging equipment and network services to the Aero Corporation to build a six-port electric vehicle DC Fast charging depot next to the Harrisburg International Airport. TurnOnGreen will provide three FSP1200 dual port 120kW DC Fast Chargers that together feature six Combined Charging System connectors capable of rapidly charging most EVs on the road today. The DC Fast Charging depot will offer charging solutions to Aero Corporation and other local area rental car companies whose customers need to recharge their rental EVs prior to returning to or departing from HIA. The company has been advised by Aero Corporation that it plans to complete installation of the DC Fast chargers in the third quarter of 2022.

07:05 EDT Karyopharm, Menarini Group receive EU authorization for Nexpovio - Karyopharm Therapeutics and the Menarini Group announced that the European Commission has granted Marketing Authorisation for NEXPOVIO, a first-in-class, oral exportin 1 inhibitor, in combination with once-weekly bortezomib and low-dose dexamethasone for the treatment of adults with multiple myeloma who have received at least one prior therapy. With this approval for the extension of NEXPOVIO's indication in the European Union, the conditional marketing authorization is now converted to a full approval. The marketing authorization, which marks the second indication for NEXPOVIO, is valid in all 27 member states of the EU as well as Iceland, Liechtenstein, Norway, and Northern Ireland. Stemline Therapeutics B.V., a wholly owned subsidiary of the Menarini Group, will be responsible for all commercialization activities in Europe. The approval follows a positive opinion granted in May 2022 by the CHMP based on results from the Phase 3 BOSTON study that demonstrated once-weekly SVd resulted in a statistically significant reduction in the risk of disease progression or death compared to standard twice-weekly bortezomib plus dexamethasone regimen. The results from the BOSTON study were published in The Lancet in November 2020. "The European Commission's approval of an expanded use of NEXPOVIO provides another option for patients with multiple myeloma who have relapsed, or become resistant to current treatment regimens," said Richard Paulson, President and Chief Executive Officer of Karyopharm. "Our decision to pursue approval for this patient population is indicative of our commitment to expand access to selinexor across the globe and we look forward to working closely with Menarini who will commercialize NEXPOVIO in Europe."

07:03 EDT Wabash announces partnership with FreightVana - Wabash announced its partnership with FreightVana, to support the 3PL's power-only offering: FreightVana X. "We're excited to see the growth in power-only models that use trailers in new and interesting ways to solve for persistent driver shortages, detention times at shippers' docks, and an overall lack of network fluidity," said Brent Yeagy, Wabash president and chief executive officer. "The transportation and logistics markets are changing, and Wabash intends to remain at the forefront of this change as a thought leader and technology partner. We've built a strong collaborative relationship with the team at FreightVana over the last year, and we believe, together, we can solve some of the transportation industry's most meaningful challenges."

07:03 EDT AutoNation to acquire CIG Financial, terms undisclosed - AutoNation announced it has entered into an agreement to acquire CIG Financial, an auto finance company headquartered in Irvine, California. The acquisition of CIG Financial aligns with AutoNation's strategic business model and focus on personalized mobility solutions. The transaction is expected to close within the next 90 days, subject to customary closing conditions and regulatory approvals.

07:01 EDT Bristol-Myers announces biopharma collaboration with Jack and Jill of America - Bristol Myers Squibb announced the first biopharma three-year exclusive collaboration with the premier African American Family Organization, Jack and Jill of America, Inc. to inspire more Black and African American individuals to join the biopharma industry to assist in creating more equity and better health outcomes for all patients through student engagement. The strategic alliance is an extension of BMS' Tomorrow's Innovators Historically Black College initiative launched with the goal of creating a sustainable bridge of talent to the biopharma industry from the HBCU community and aligns with BMS's inclusion and diversity health equity commitments to increase workforce representation by creating and sustaining a pipeline of diverse talent.

06:58 EDT Travelers reports Q2 book value per share of $96.39 - Book value per share of $96.39, down 18% from June 30, 2021 driven by higher interest rates; adjusted book value per share of $112.37, up 8% from June 30, 2021.

06:50 EDT Boeing, Cargolux announce 777-8 Freighter as replacement for 747-400 fleet - Boeing and Cargolux announced that Europe's largest all-cargo airline has selected the 777-8 Freighter as the preferred solution to replace its 747-400 fleet. The selection was announced at the Farnborough International Airshow.

06:42 EDT AT&T raises FY Mobility service revenue guidance to 4.5%-5% - "We're expanding our customer base at an accelerated pace across our twin engines of growth - 5G and fiber," said John Stankey, AT&T CEO. "We're rapidly building out our best-in-class networks on the heels of record-level connectivity investment. We've already added nearly 2 million AT&T Fiber locations this year and just reached our target of covering 70 million people with mid-band 5G spectrum two quarters early, with expectations to now approach the 100 million mark by the end of year." "As a result of our higher-than-forecasted customer growth, we're increasing our Mobility service revenue guidance to 4.5-5% growth for the full year. We're also decreasing full-year free cash flow guidance to the $14 billion range to reflect heavy investment in growth and working capital impacts related to timing of collections. Our results the last eight quarters demonstrate that our deliberate strategy of focusing on growth is helping us gain valuable customer relationships, and we're confident in our ability to maintain this momentum while also continuing to reduce debt and deliver an attractive dividend."

06:41 EDT AT&T reports Q2 813,000 postpaid phone net adds - Q2: Mobility: 813,000 postpaid phone net adds; 1,058,000 postpaid net adds; 196,000 prepaid phone net adds Postpaid phone churn of 0.75%; Revenues up 5.2% year over year; service revenues up 4.6%; equipment revenues up 7.2%; Operating income of $6.2 billion, up 3.4% year over year; EBITDA up 2.5%; Operating income margin of 31.2%; EBITDA service margin 54.8%. Business Wireline: Operating income margin of 12.7%; EBITDA margin 36.2%.Consumer Wireline: 316,000 AT&T Fiber net adds; fiber penetration of nearly 37%; Broadband revenues up 5.6% year over year due to fiber revenue growth of nearly 28%; Broadband ARPU growth of 5.3%.

06:38 EDT Acutus Medical names David Roman as CEO - Acutus Medical announced that David Roman has been appointed President and CEO, and member of the Board of Directors, effective immediately. Roman, who joined the company as CFO in March 2021, has also been serving as Interim CEO since May 13, 2022. He will continue as CFO until a replacement is determined.

06:32 EDT Snap-On sees 2022 CapEx $90M-$100M - COVID-19 and its subsequent variants, as well as supply chain inefficiencies, continue to impact economic activity worldwide in 2022. The company believes that our markets and our operations possess and, indeed, have demonstrated considerable resilience against the impact of the virus and that there will be ongoing advancement even in the midst of the turbulence. The trajectory, however, may be uncertain due to the evolving nature of the situation. Snap-on expects to make continued progress in 2022 along its defined runways for coherent growth, leveraging capabilities already demonstrated in the automotive repair arena and developing and expanding its professional customer base, not only in automotive repair, but in adjacent markets, additional geographies and other areas, including extending in critical industries, where the cost and penalties for failure can be high. In pursuit of these initiatives, the company anticipates that capital expenditures in 2022 will be in a range of $90 million to $100 million, of which $41.5 million was incurred in the first six months of the year. Snap-on continues to respond to the global macroeconomic challenges through its Rapid Continuous Improvement process and other cost reduction initiatives. Snap-on currently anticipates that its full year 2022 effective income tax rate will be in the range of 23% to 24%.

06:18 EDT Equifax to acquire LawLogix, terms undisclosed - Equifax announced that it has signed a definitive agreement to acquire LawLogix, a provider of cloud-based I-9 software and immigration case management software, from Hyland. This acquisition will enable Equifax's business, Workforce Solutions, to support employers and law firms. Based in Phoenix, LawLogix digitizes and streamlines I-9 and immigration processes while helping thousands of organizations comply with regulatory frameworks. No other parts of the Hyland business are included in the transaction. The transaction is subject to customary closing conditions and is expected to close in the third quarter of 2022. The acquisition is not anticipated to have a material impact on 2022 Equifax financial results.

06:14 EDT Terran Orbital commissions Fleet Space CENTAURI-5 payload - Terran Orbital announced the commissioning of the Fleet Space CENTAURI-5 payload. The payload provides Machine to Machine (M2M) and Internet of Things connectivity to ground terminals and is an improved version of the payloads flown on CENTAURI-3 and CENTAURI-4. Fleet Space Technologies enlisted Tyvak International SRL, Terran Orbital's wholly-owned international subsidiary, to design, build, and integrate the 6U microsat weighing in at 12 kg. Mission operations are now shared between Terran Orbital and Fleet Space as the Low Earth Orbit satellite brings new capabilities to the existing Fleet constellation and the forthcoming Alpha constellation. Both constellations are operated by Fleet Space in collaboration with Terran Orbital.

06:12 EDT Doma Holdings names Mike Smith as CFO - Doma Holdings (DOMA) announced the appointment of Mike Smith as CFO as of July 19. Previously, Mike was serving as the company's Chief Accounting Officer and Acting CFO, building on his experience at Doma and extensive background as a senior finance executive. Prior to joining Doma as Chief Accounting Officer, Mike served as Chief Accounting Officer and Director of Treasury at Banc of California (BANC).

06:10 EDT TRI Pointe ends Q2 with record sold backlog of nearly $3B - "Tri Pointe ended the second quarter with a record sold backlog of nearly $3 billion, putting us in an excellent position to continue delivering strong top- and bottom-line results for the remainder of the year," said Tri Pointe Homes President and COO Tom Mitchell. "We believe that our approach of acquiring land in prime locations close to employment and transportation centers and other lifestyle amenities that homebuyers value, combined with our innovative, premium homes, gives us a distinct selling advantage in a challenging market. We also have strong leadership teams at both the local and national levels who have successfully navigated prior housing cycles and are skilled at operating through such times. Given these positives, we remain as confident as ever in the long-term outlook for Tri Pointe Homes."

06:06 EDT TRI Pointe sees Q3 home deliveries 1,300-1,500 - For the third quarter, the company anticipates delivering between 1,300 and 1,500 homes at an average sales price between $700,000 and $715,000. The Company expects homebuilding gross margin percentage to be in the range of 26.0% to 27.0% for the third quarter and anticipates its SG&A expense as a percentage of home sales revenue will be in the range of 10.0% to 11.0%. Finally, the Company expects its effective tax rate for the third quarter to be in the range of 25.0% to 26.0%. Due to quickly changing market conditions and significant uncertainty related to the broader economy, the company is providing guidance for the third quarter and is not providing updated guidance for the full year at this time.

05:56 EDT Roche sees FY22 sales stable or up in low single digits - Sales are expected to be stable or grow in the low-single digits at constant exchange rates. Core earnings per share are targeted to grow in the low- to mid-single digit range at constant exchange rates, including the accretive effect of the 2021 share repurchase. Roche expects to further increase its dividend in Swiss francs. Roche anticipates sales of COVID-19 medicines and diagnostics to decrease by approximately CHF 2 billion to around CHF 5 billion, and sales losses due to biosimilars in the current year to be roughly CHF 2.5 billion. Excluding those effects, Group sales are expected to grow in the high-single digit range.

05:46 EDT Roche CEO Severin Schwan to step down, to be succeeded by Thomas Schinecker - Roche announced that Christoph Franz has decided not to seek re-election to the Board of Directors at the AGM in March 2023. The Board of Directors intends to propose Severin Schwan as new Chairman at the AGM and has appointed Thomas Schinecker as new Roche CEO effective 15 March 2023. Christoph Franz was elected to the Roche Board of Directors in 2011 and has served as its Chairman since 2014: "After serving twelve years on the Board of Directors, nine of which as Chairman, I have decided not to seek re-election to the Board next year. We have achieved many important milestones and with the conclusion of Roche's 125th anniversary, it is now the right time for a change in leadership." Schwan has been a member of the Corporate Executive Committee since 2006 and has served as CEO of the company since 2008. Schinecker is currently CEO of the Diagnostics Division.

05:35 EDT NetEase Cloud Music granted right to distribute YG Entertainment music catalog - Cloud Village announced that it has entered into a licensing agreement for digital music distribution with YG Entertainment, granting NetEase Cloud Music the right to distribute YG Entertainment's music catalog in China. Under the terms of the agreement, both parties will engage in approaches to unlock more opportunities for YG Entertainment's catalog as well as its artists on the platform, including music by popular K-Pop groups such as BIGBANG and BLACKPINK.

05:30 EDT Addex Therapeutics reduces nominal value of shares - Addex Therapeutics announced the reduction of the nominal value of its issued, authorized and conditional share capital from CHF 1.00 to CHF 0.01, following the expiration of a period of two months after the third creditor call in The Swiss Gazette of Commerce in accordance with article 732 of Swiss Code of Obligations. The reduction was accepted by shareholders at the annual general meeting held on May 9. The issued share capital remains at 65,272,952 shares and the authorized and conditional capital remain at 32,636,476 shares, respectively. The revised nominal value of CHF0.01 is expected to become effective on the SIX Swiss Exchange on July 26.

05:22 EDT SAP backs FY22 cloud revenue view up 23%-26% - Sees FY22 free cash flow above EUR 4.5B.

05:10 EDT Clarivate awarded expanded license for domain service in China - Clarivate announced it is the first and only licensed foreign-owned domain name registrar in Mainland China to offer a wide range of Top Level Domains including .com, .net, .cn and others to companies hosting website content locally. By launching a new registrar service in Mainland China through its corporate domain registrar, MarkMonitor Information Technology, Clarivate provides a domain management solution for customers operating live websites and holding domains in Mainland China.

05:05 EDT Yum China starts construction on Jiading district supply chain management center - Yum China announced that the company has commenced the construction of the Yum China Supply Chain Management Center in Shanghai's Jiading district. The 61,000 square meter facility is Yum China's largest greenfield supply chain center project to date. The site is scheduled for completion in 2024 and will serve as the headquarters of the company's supply chain operations. In addition to supporting Yum China's restaurants in eastern China, the new facility will serve as an integrated cold chain transit hub for the region and support the company's operations across the country. It will include ambient temperature storage, cold-chain storage, office space and supporting facilities. The company will adopt modern automation solutions, three-dimensional storage technology to optimize the use of the storage space, and leverage the latest digital technologies to build a smart supply chain management platform. The company will also deploy rooftop solar panels and wind power generation equipment to reduce carbon emissions.